Advertisement

Drugs

, Volume 53, Issue 4, pp 563–582 | Cite as

Cyclo-Oxygenase Isoenzymes

How Recent Findings Affect Thinking About Nonsteroidal Anti-Inflammatory Drugs
  • Jean-Yves Jouzeau
  • Bernard Terlain
  • Amr Abid
  • Emmanuelle Nédélec
  • Patrick Netter
Review Article

Summary

The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarities, but are specifically regulated at the molecular level and may be distinguished apart in their functions, although some physiological overlap between them does occur.

The major goal in developing selective COX inhibitors is to improve NSAID tolerability. Classic NSAIDs preferentially inhibit COX-1 in vitro, but it appears hazardous to judge their gastrointestinal (GI) safety profile from these data. New compounds with a high selectivity for COX-2, especially those that are non-acidic, may be better tolerated in the GI tract.

While these compounds also might have a potential use in various diseases such as colorectal cancer and neurodegenerative diseases of the Alzheimer type, the possible appearance of adverse effects, perhaps renally-related, must be taken into consideration. Finally, well-designed large clinical trials are required to adequately estimate both the promising therapeutic advantages that may be offered by highly selective NSAIDs, and the potential drawbacks that may be inherent with prolonged COX-2 inhibition.

Keywords

Adis International Limited Nimesulide Meloxicam Etodolac Nabumetone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5PubMedGoogle Scholar
  2. 2.
    Smith WL, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 1971; 231: 235–7PubMedGoogle Scholar
  3. 3.
    Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol 1971; 231: 237–9PubMedGoogle Scholar
  4. 4.
    Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33–67PubMedGoogle Scholar
  5. 5.
    Cronstein BN, Weissmann G. Target for anti-inflammatory drugs. Ann Rev Pharmacol Toxicol 1995; 35: 449–62Google Scholar
  6. 6.
    Flower RJ, Vane JR. Inhibition of prostaglandin synthase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature New Biol 1972; 240: 410–1Google Scholar
  7. 7.
    Whittle BJR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature New Biol 1980; 284: 271–3Google Scholar
  8. 8.
    Vane JR. Prostaglandins and the aspirin-like drugs. Hosp Pract 1972; 7: 61–71Google Scholar
  9. 9.
    Lysz TW, Needleman P. Evidence for two distinct forms of fatty acid cyclooxygenase in brain. J Neurochem 1982; 38: 1111–7PubMedGoogle Scholar
  10. 10.
    Preston SJ, Arnold MH, Beller EM, et al. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicyclic acid (aspirin) in rheumatoid arthritis. Br J Pharmacol 1989; 27: 607–11Google Scholar
  11. 11.
    Abramson SB, Weissmann G. The mechanism of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1–9PubMedGoogle Scholar
  12. 12.
    McCormack K. Non steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43PubMedGoogle Scholar
  13. 13.
    Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737–40PubMedGoogle Scholar
  14. 14.
    Masferrer JL, Zweifel BS, Seibert K, et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375–9PubMedGoogle Scholar
  15. 15.
    Raz A, Wyche A, Needlman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phase. Proc Natl Acad Sci USA 1989; 86: 1657–61PubMedGoogle Scholar
  16. 16.
    Ristimäki A, Garfinkel S, Wessendorf J, et al. Induction of cyclooxygenase-2 by interleukin-1α. J Biol Chem 1994; 269: 11769–75PubMedGoogle Scholar
  17. 17.
    DuBois RN, Tsujii M, Bishop P, et al. Cloning and characterization of growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994; 266: G822–7PubMedGoogle Scholar
  18. 18.
    Sirois J, Richards JS. Transcriptional regulation of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. J Biol Chem 1993; 268: 21931–8PubMedGoogle Scholar
  19. 19.
    Kujubu DA, Reddy ST, Fletcher BS, et al. Expression of the protein product of prostaglandin synthase-2/TIS 10 gene in mitogen-stimulated swiss 3T3 cells. J Biol Chem 1991; 268: 5425–30Google Scholar
  20. 20.
    Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692–6PubMedGoogle Scholar
  21. 21.
    O’Bannion MK, Sadowski HB, Winn V, et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261–7Google Scholar
  22. 22.
    DeWitt DL, Meade E, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993; 95: 40S–4SPubMedGoogle Scholar
  23. 23.
    Vane JR. Towards a better aspirin. Nature New Biol 1994; 367: 215–6Google Scholar
  24. 24.
    Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perpect 1994; 7: 501–11Google Scholar
  25. 25.
    Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083: 1–17PubMedGoogle Scholar
  26. 26.
    Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62: 167–215PubMedGoogle Scholar
  27. 27.
    Kulmacz R J, Pendleton RB, Lands WEM. Interaction between peroxidase and cyclooxygenase activities in prostaglandinendoperoxide synthase. Biochemistry 1994; 33: 5428–39PubMedGoogle Scholar
  28. 28.
    Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 1992; 25: 249–65Google Scholar
  29. 29.
    Percival MD, Ouellet M, Vincent CJ, et al. Purification and characterization of recombinant human cyclooxygenase-2. Arch Biochem Biophys 1994; 315: 111–8PubMedGoogle Scholar
  30. 30.
    Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzyme by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610–4PubMedGoogle Scholar
  31. 31.
    Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 213–22PubMedGoogle Scholar
  32. 32.
    Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125–40PubMedGoogle Scholar
  33. 33.
    Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270: G393–400PubMedGoogle Scholar
  34. 34.
    Appleby SB, Ristimäki A, Neilson K, et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723–7PubMedGoogle Scholar
  35. 35.
    Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994; 221: 889–97PubMedGoogle Scholar
  36. 36.
    Lyons-Giordano B, Pratta MA, Galbraith W, et al. Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. Exp Cell Res 1993; 206: 58–62PubMedGoogle Scholar
  37. 37.
    Srivastava KS, Tetsuka T, Daphna-Iken D, et al. IL-1β stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 1994; 267: F504–8PubMedGoogle Scholar
  38. 38.
    DeWitt DL, Meade E. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch Biochem Biophys 1993; 306: 94–102PubMedGoogle Scholar
  39. 39.
    Ristimäki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996; 318: 325–31PubMedGoogle Scholar
  40. 40.
    Hoff T, DeWitt DL, Kaever V, et al. Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett 1993; 320: 38–42PubMedGoogle Scholar
  41. 41.
    Xie W, Fletcher BS, Andersen RD, et al. v-src induction of the TIS 10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol Cell Biol 1994; 14: 6531–9PubMedGoogle Scholar
  42. 42.
    Inoue H, Nanayama T, Hara S, et al. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase-2 gene in differentiated U937 monocytic cells. FEBS Lett 1994; 350: 51–4PubMedGoogle Scholar
  43. 43.
    Coleman RA, Smith WL, Narumiya S. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205–29PubMedGoogle Scholar
  44. 44.
    Xie W, Merrill JR, Bradshaw WS, et al. Structural determination and promoter analysis of the chicken mitogen-inducible prostaglandin G/H synthase gene and genetic mapping of the murine homologue. Arch Biochem Biophys 1993; 300: 247–52PubMedGoogle Scholar
  45. 45.
    Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IkBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–6PubMedGoogle Scholar
  46. 46.
    Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270: 286–9PubMedGoogle Scholar
  47. 47.
    Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993; 307: 169–77Google Scholar
  48. 48.
    O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–60PubMedGoogle Scholar
  49. 49.
    Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013–7PubMedGoogle Scholar
  50. 50.
    Yamagata K, Anderasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neuron: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371–86PubMedGoogle Scholar
  51. 51.
    Iseki S. Immunocytochemical localization of cyclooxygenase-1 and -2 in the rat stomach. Histochem J 1995; 27: 323–8PubMedGoogle Scholar
  52. 52.
    Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996; 713: 64–9PubMedGoogle Scholar
  53. 53.
    Breder CD, DeWitt DL, Kraig RP. Characterization of inducible cyclooxygenase in the rat brain. J Comp Neurol 1995; 355: 296–315PubMedGoogle Scholar
  54. 54.
    Seibert K, Masferrer JL, Zhang Y, et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions 1995; 46 Suppl.: 41–50Google Scholar
  55. 55.
    Smith WL, Wilkin GP. Immunochemistry of prostaglandin endoperoxide forming cyclooxygenases: the detection of cyclooxygenases in rat, rabbit, and guinea pig kidneys by immunofluorescence. Prostaglandins 1977; 13: 873–92PubMedGoogle Scholar
  56. 56.
    Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–10PubMedGoogle Scholar
  57. 57.
    Morita I, Schinder M, Regier MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 10902–8PubMedGoogle Scholar
  58. 58.
    Yu K, Bayowa Y, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975–83PubMedGoogle Scholar
  59. 59.
    Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-actived receptor β and promotes adipocyte differentiation. Cell 1995; 83: 813–9PubMedGoogle Scholar
  60. 60.
    Murakami M, Matsumoto R, Austen KF, et al. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994; 269: 22269–75PubMedGoogle Scholar
  61. 61.
    Kawata R, Reddy ST, Wolner B, et al. Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cell. J Immunol 1995; 155: 818–25PubMedGoogle Scholar
  62. 62.
    Karim S, Habib A, Levy-Toledano S, et al. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042–8PubMedGoogle Scholar
  63. 63.
    Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483–92PubMedGoogle Scholar
  64. 64.
    Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473–82PubMedGoogle Scholar
  65. 65.
    Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406–9PubMedGoogle Scholar
  66. 66.
    Picot D, Loll PJ, Garavito M. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243–9PubMedGoogle Scholar
  67. 67.
    Blake C. Prostaglandin synthase: at the heart of the matter. Curr Biol 1994; 4: 452–4PubMedGoogle Scholar
  68. 68.
    DeWitt DL, El-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxydes synthases. J Biol Chem 1990; 265: 5192–8PubMedGoogle Scholar
  69. 69.
    Tsai AL, Kulmacz RJ, Palmer G. Spectroscopic evidence for reaction of prostaglandin H synthase-1 tyrosyl radical with arachidonic acid. J Biol Chem 1995; 270: 10503–8PubMedGoogle Scholar
  70. 70.
    Loll PJ, Picot D, Garavito M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct Biol 1995; 2: 637–43PubMedGoogle Scholar
  71. 71.
    Kulmacz RJ. Topography of prostaglandin H synthase. J Biol Chem 1989; 264: 14136–44PubMedGoogle Scholar
  72. 72.
    Loll PJ, Picot D, Ekabo O, et al. Synthesis and use of iodinated nonsteroidal anti-inflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996; 35: 7330–40PubMedGoogle Scholar
  73. 73.
    Mancini JA, Riendeau D, Falgueyret JP, et al. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 1995; 270: 29372–7PubMedGoogle Scholar
  74. 74.
    Bhattacharyya DK, Lecomte M, Ricke CJ, et al. Involvement of Arginine 120, Glutamate 524, and Tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996; 271: 2179–84PubMedGoogle Scholar
  75. 75.
    Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs — differences and similarities. N Engl J Med 1991; 324: 1716–25PubMedGoogle Scholar
  76. 76.
    Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclo-oxygenase-2. Nature Struct Biol 1996; 3: 927–33PubMedGoogle Scholar
  77. 77.
    Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of non steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–7PubMedGoogle Scholar
  78. 78.
    Laneuville O, Breuer DK, DeWitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927–34PubMedGoogle Scholar
  79. 79.
    Lecomte M, Laneuville O, Chuan J, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207–15PubMedGoogle Scholar
  80. 80.
    Mancini JA, O’Neill GP, Bayly C, et al. Mutation of serine 516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett 1994; 342: 33–7PubMedGoogle Scholar
  81. 81.
    Allen KN. Aspirin — now we can see it. Nature Med 1995; 1: 882–3PubMedGoogle Scholar
  82. 82.
    Wennogle LP, Liang H, Quintavalla JC, et al. Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett 1995; 371: 315–20PubMedGoogle Scholar
  83. 83.
    Garavito RM, Picot D, Loll PL. The x-ray structures of complexes of cyclooxygenase-1 and inhibitors. Med Chem Res 1995; 5: 375–83Google Scholar
  84. 84.
    Gierse JK, McDonald JJ, Hauser SD, et al. A single aminoacid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271: 15810–4PubMedGoogle Scholar
  85. 85.
    Rome LH, Lands WEM. Structural requirements for time-dependent inhibition of prostanglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975; 72: 4863–5PubMedGoogle Scholar
  86. 86.
    Kulmacz RJ, Lands WEM. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985; 260: 12572–8PubMedGoogle Scholar
  87. 87.
    Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994; 91: 11202–6PubMedGoogle Scholar
  88. 88.
    Ouellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995; 306: 247–51PubMedGoogle Scholar
  89. 89.
    DeWitt DL, Bhattacharyya D, Lecomte M, et al. The differential susceptibility of prostaglandin endoperoxyde H synthase-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res 1995; 5: 325–43Google Scholar
  90. 90.
    Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase / cyclooxygenase activity. Arzneimittel Forschung 1995; 45: 1096–8PubMedGoogle Scholar
  91. 91.
    Bhattacharyya DK, Lecomte M, Dunn J, et al. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys 1995; 317: 19–24PubMedGoogle Scholar
  92. 92.
    Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase / cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55–9PubMedGoogle Scholar
  93. 93.
    Barnett J, Chow J, Ives D, et al. Purification, characterization and selective inhibition of human prostaglandin G/H Synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209: 130–9PubMedGoogle Scholar
  94. 94.
    O’Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccina virus. Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994; 45: 245–54PubMedGoogle Scholar
  95. 95.
    Glaser K, Sung M-L, O’Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281: 107–11PubMedGoogle Scholar
  96. 96.
    Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible of human cyclooxygenase. Biochem J 1995; 305: 479–84PubMedGoogle Scholar
  97. 97.
    Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism: part 1. In vitro findings. Biochem Pharmacol 1996; 51: 21–8PubMedGoogle Scholar
  98. 98.
    Chan CC, Boyce S, Bribeau C, et al. Pharmacology of selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non human primate stomach. J Pharmacol Exp Ther 1995; 274: 1531–7PubMedGoogle Scholar
  99. 99.
    Klein T, Nusing RM, Pfeilschifter J, et al. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994; 48: 1605–10PubMedGoogle Scholar
  100. 100.
    Churchill L, Graham AG, Shih CK, et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996; 4: 125–35Google Scholar
  101. 101.
    Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biological efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68–74PubMedGoogle Scholar
  102. 102.
    Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705–12PubMedGoogle Scholar
  103. 103.
    Panara MR, Greco A, Santini G, et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-me-thanesulphonamido — 6 — (2,4 — difluorothiophenyl) — 1 — indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthase. Br J Pharmacol 1995; 116: 2429–34PubMedGoogle Scholar
  104. 104.
    Young JM, Panah S, Satchawatcharaphong C, et al. Human whole blood assays for inhibition of prostaglandin G/H synthase-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 1996; 45: 246–53PubMedGoogle Scholar
  105. 105.
    Grossman CJ, Wiseman J, Lucas LS, et al. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 2 inhibitors. Inflamm Res 1995; 44: 253–57PubMedGoogle Scholar
  106. 106.
    Hayllar J, Bjarnason I. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1995; 346: 521–2PubMedGoogle Scholar
  107. 107.
    Vane JR. NSAIDs, COX-2 inhibitors, and the gut [letter]. Lancet 1995; 346: 521–2Google Scholar
  108. 108.
    Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. Scand J Rheumatol 1996; 25Suppl 102: 9–21Google Scholar
  109. 109.
    Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationals for selective inhibition and progress to date. Med Res Rev 1996; 16: 181–206PubMedGoogle Scholar
  110. 110.
    Cipollone F, Ganci A, Panara, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995; 58: 335–41PubMedGoogle Scholar
  111. 111.
    Tofanetti O, Casciarri I, Cipolla PV, et al. Effects of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 1989; 17: 745–6Google Scholar
  112. 112.
    Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228–32PubMedGoogle Scholar
  113. 113.
    Richardson C, Emery P. The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf 1996; 15: 249–60PubMedGoogle Scholar
  114. 114.
    Simon LS. Non steroidal antiinflammatory drugs and their effects. The importance of COX ‘selectivity’. J Clin Rheumatol 1996; 2: 135–40PubMedGoogle Scholar
  115. 115.
    Aslanian R, Carrathers NI, Kaminski JJ. Cyclooxygenase-2: a novel target for therapeutic intervention. Expert Opin Invest Drugs 3: 1323–5, 1994Google Scholar
  116. 116.
    Jensen NP. NSAIDs revisited cyclooxygenase 2 (COX-2) inhibitors. Med Chem Res 1995; 5: 319–24Google Scholar
  117. 117.
    Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105–10PubMedGoogle Scholar
  118. 118.
    Wiesenberg-Böttcher I, Schweizer A, Green JR, et al. The pharmacological profile of CGP-28238, a highly potent anti-inflammatory compound. Agents Actions 1989; 26: 240–2PubMedGoogle Scholar
  119. 119.
    Swingle KF, Moore GI, Grant TJ. 4-nitro-2-phenoxymethane-sulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn Ther 1976; 221: 131–9Google Scholar
  120. 120.
    Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180–7PubMedGoogle Scholar
  121. 121.
    Wong S, Lee SJ, Frierson MR, et al. Antiarthritic profile of BF-389. A novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992; 37: 90–8PubMedGoogle Scholar
  122. 122.
    Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1–10PubMedGoogle Scholar
  123. 123.
    Prasit P, Black WC, Chan CC, et al. L745,337: a selective cyclooxygenase-2 inhibitor. Med Chem Res 1995; 5: 364–74Google Scholar
  124. 124.
    Tanaka K, Makino S, Shimotori T, et al. Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1 -benzopyran-4-one. 2nd communication: effect on the arachidonic acid cascades. Arzneimittel Forschung 1992; 42: 945–50PubMedGoogle Scholar
  125. 125.
    Reitz DB, Li JJ, Norton MB, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 1994; 37: 3878–81PubMedGoogle Scholar
  126. 126.
    Reitz DB, Li JJ, Norton MB, et al. Novel 1,2-diarylcyclopentenes are selective, potent, and orally active cyclooxygenase inhibitors. Med Chem Res 1995; 5: 351–63Google Scholar
  127. 127.
    Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study [abstract]. Arthritis Rheum 1996; 39Suppl. 9: S 226Google Scholar
  128. 128.
    Tanaka K, Kawasaki H, Kurata K, et al. T-614, a novel anti rheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995; 67: 305–14PubMedGoogle Scholar
  129. 129.
    Anderson GD, Hauser SD, McGarity KL, et al. Selective inhibition of cyclooxygenase (COX-2) reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672–9PubMedGoogle Scholar
  130. 130.
    Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittel Forschung 1995; 45(II): 1093–5PubMedGoogle Scholar
  131. 131.
    Taniguchi Y, Ikesue A, Yokoyama K, et al. Selective inhibition by nimesulide, a novel non steroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in vitro. Pharm Res 1995; 1: 173–5Google Scholar
  132. 132.
    Vojnovic I, Amirmansour C, Warner TD, et al. Nimesulide: selectivity for COX-2 over COX-1 [abstract P4], William Harvey Research Conferences on improved non-steroid anti-inflammatory drugs; COX-2 enzyme inhibitors; 1995 Oct 10–11: LondonGoogle Scholar
  133. 133.
    Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423–33PubMedGoogle Scholar
  134. 134.
    Futaki N, Arai I, Hamasaka Y, et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993; 45: 753–5PubMedGoogle Scholar
  135. 135.
    Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54PubMedGoogle Scholar
  136. 136.
    Kankaanranta H, Moilanen E, Vapaatalo H. Effects of non steroidal anti-inflammatory drugs on polymorphonuclear leukocytes functions in vitro: focus on fenamates. Arch Pharmacol 1994; 350: 685–91Google Scholar
  137. 137.
    Tanaka K, Shimotori T, Makino S, et al. Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1 -benzopyran-4-one. 1st communication: Anti-inflammatory, analgesic and other related properties. Arzneimittel Forschung 1992; 42: 935–44PubMedGoogle Scholar
  138. 138.
    Magni E. The effect of nimesulide on prostanoid formation. Drugs 1993; 46Suppl. 1: 10–4PubMedGoogle Scholar
  139. 139.
    Pairet M, Engelhardt E. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 1996; 10: 1–15Google Scholar
  140. 140.
    Frölich JC. Prostaglandin endoperoxide synthase isoenzymes: the clinical relevance of selective inhibition. Ann Rheum Dis 1995; 54: 942–3PubMedGoogle Scholar
  141. 141.
    Noble S, Balfour JA. Meloxicam. Drugs 1996; 51: 424–30PubMedGoogle Scholar
  142. 142.
    Furst DE. Are there differences among nonsteroidal anti-inflammatory drugs? Arthritis Rheum 1994; 37: 1–9PubMedGoogle Scholar
  143. 143.
    Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993; 88: 1318–23PubMedGoogle Scholar
  144. 144.
    Lichtenstein DR, Syngal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995; 38: 5–18PubMedGoogle Scholar
  145. 145.
    Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156: 1623–8Google Scholar
  146. 146.
    Fries JF, Miller SR, Williams CA, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647–55PubMedGoogle Scholar
  147. 147.
    Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86: 449–58PubMedGoogle Scholar
  148. 148.
    Price AH, Fletcher M. Mechanisms of NSAID-induced gastroenteropathy. Drugs 1990; 40Suppl. 5: 1–11PubMedGoogle Scholar
  149. 149.
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787–96PubMedGoogle Scholar
  150. 150.
    Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med 1996; 100Suppl. 2A: 31S–6SPubMedGoogle Scholar
  151. 151.
    Lichtenberger LM, Graziani LA, Dial EJ, et al. Role of surface-active phospholipids in gastric cytoprotection. Science 1983; 219: 1327–9PubMedGoogle Scholar
  152. 152.
    Lichtenberger LM, Wang Z-M, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associated with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154–8PubMedGoogle Scholar
  153. 153.
    Somasundaram S, Hayllar H, Rafi S, et al. The biochemical basis of non-steroidal anti-inflammatory drug induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289–99PubMedGoogle Scholar
  154. 154.
    Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996; 55: 211–3PubMedGoogle Scholar
  155. 155.
    Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989; 24Suppl. 163: 9–16Google Scholar
  156. 156.
    Scarpignato C. Nonsteroidal anti-inflammatory drugs: How do they damage gastroduodenal mucosa? Dig Dis 1995; 13Suppl. 1: 9–39PubMedGoogle Scholar
  157. 157.
    Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990; 259: G462–7PubMedGoogle Scholar
  158. 158.
    Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastro-mucosal injury. Am J Physiol 1993; 265: G993–8PubMedGoogle Scholar
  159. 159.
    Santucci L, Fiorucci S, Giansanti M, et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994; 35: 909–15PubMedGoogle Scholar
  160. 160.
    Appleyard CB, McCafferty DM, Tigley AW, et al. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996; 270: G42–8PubMedGoogle Scholar
  161. 161.
    Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99: 607–11PubMedGoogle Scholar
  162. 162.
    Tepperman BL, Whittle BJR. Endogenous nitric oxide and sensory neuropeptides interact in the modulation of rat gastric microcirculation. Br J Pharmacol 1992; 105: 171–5PubMedGoogle Scholar
  163. 163.
    Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994; 15: 405–6PubMedGoogle Scholar
  164. 164.
    Corbett JA, Kwon G, Turk J, et al. IL-1 β induces the cooexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767–70PubMedGoogle Scholar
  165. 165.
    Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 1995; 33: 179–207PubMedGoogle Scholar
  166. 166.
    Salvemini D, Misko TP, Masferrer JL, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240–4PubMedGoogle Scholar
  167. 167.
    Salvemini D, Seibert K, Masferrer JL, et al. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994; 93: 1940–7PubMedGoogle Scholar
  168. 168.
    Lee M, Feldman M. Nonessential role of leukotrienes as mediators of acute gastric mucosal injury induced by aspirin. Dig Dis Sci 1992; 37: 1282–7PubMedGoogle Scholar
  169. 169.
    Wallace JL, McCafferty DM, Carter L, et al. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? Gastroenterology 1993; 105: 1630–6PubMedGoogle Scholar
  170. 170.
    Rainsford KD. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions 1987; 21: 316–9PubMedGoogle Scholar
  171. 171.
    Vaananen PM, Keenan CM, Grisham MB, et al. A pharmacological investigation of the role of leukotrienes in the patho-genesis of experimental NSAIDs — gastropathy. Inflammation 1992; 16: 227–40PubMedGoogle Scholar
  172. 172.
    Schrier DJ, Baragi VM, Connor DT, et al. The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-l,3,4-thiadiazole-2(3H)-thione, choline salt (CI-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation. Prostaglandins 1994; 47: 17–30PubMedGoogle Scholar
  173. 173.
    Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with a potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994; 271: 1399–1408PubMedGoogle Scholar
  174. 174.
    Rainsford KD, Tsang S, Hunt RH, et al. Effects of non-steroidal anti-inflammatory drugs on prostaglandin H synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture. Inflammopharmacology 1995; 3: 299–310Google Scholar
  175. 175.
    Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles: fact or fiction? Drug Saf 1994; 10: 183–95PubMedGoogle Scholar
  176. 176.
    Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–63PubMedGoogle Scholar
  177. 177.
    Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85–9PubMedGoogle Scholar
  178. 178.
    Savage RL, Moller PW, Ballantyne CL et al. Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum 1993; 36: 84–90PubMedGoogle Scholar
  179. 179.
    Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078–88PubMedGoogle Scholar
  180. 180.
    Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedGoogle Scholar
  181. 181.
    Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72PubMedGoogle Scholar
  182. 182.
    Kurata JH, Nagawa AN, Abbey DE, et al. A prospective study of risk for peptic ulcer disease in seventh day adventists. Gastroenterology 1992; 102: 902–9PubMedGoogle Scholar
  183. 183.
    Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. Arch Intern Med 1995; 155: 1371–7PubMedGoogle Scholar
  184. 184.
    Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol 1996; 25Suppl. 102: 3–8Google Scholar
  185. 185.
    Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions — 2. BMJ 1986; 292: 1190–1Google Scholar
  186. 186.
    Bateman DN. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994; 343: 1051–2PubMedGoogle Scholar
  187. 187.
    Henry D, Lim LY, Garcia-Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6PubMedGoogle Scholar
  188. 188.
    Rainsford KD, Quadir M. Gastrointestinal damage and bleeding from non-steroidal anti-inflammatory drugs: I. Clinical and epidemiological aspects. Inflammopharmacology 1995; 3: 169–90Google Scholar
  189. 189.
    Brune K, Rainsford KD, Wagner K, et al. Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages. Arch Pharmacol 1981; 315: 269–76Google Scholar
  190. 190.
    Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987; 83: 25–30PubMedGoogle Scholar
  191. 191.
    Lanza F, Rack MF, Lynn M, et al. An endoscopie comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987; 14: 338–41PubMedGoogle Scholar
  192. 192.
    Bianchi-Porro G, Caruso I, Petrillo M, et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med 1991; 229: 5–8PubMedGoogle Scholar
  193. 193.
    Jenner PN. A 12-month postmarketing surveillance study of nabumetone: a preliminary report. Drugs 1990; 40Suppl. 5: 80–6PubMedGoogle Scholar
  194. 194.
    Stroehmann I, Fedder M, Zeidler H. German drug monitoring studies with nabumetone. Drugs 1990; 40Suppl. 5: 38–42PubMedGoogle Scholar
  195. 195.
    Wilkens RF. An overview of the long-term safety experience of nabumetone. Drugs 1990; 40Suppl. 5: 34–7Google Scholar
  196. 196.
    Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56–65PubMedGoogle Scholar
  197. 197.
    Dandona P, Jeremy JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects: does nabumetone provide a solution? Drugs 1990; 40Suppl. 5: 16–24PubMedGoogle Scholar
  198. 198.
    Blower PR. The unique pharmacologic profile of nabumetone. J Rheumatol 1992; 19Suppl. 36: 13–20Google Scholar
  199. 199.
    Marini U, Spotti D. Gastric tolerability of nimesulide: a double-blind comparison of 2 oral dosage regimens and placebo. Drugs 1993; 46Suppl. 1: 249–52PubMedGoogle Scholar
  200. 200.
    Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parrallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35Suppl. 1: 61–97PubMedGoogle Scholar
  201. 201.
    Cipollini F, Mecozzi V, Altilia F. Endoscopic assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr Ther Res 1989; 45: 1042–8Google Scholar
  202. 202.
    Pochobradsky MG, Mele G, Beretta A. Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 1991; 17: 197–204PubMedGoogle Scholar
  203. 203.
    Dreiser RL, Benvelli DC. Long-term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs 1993; 46Suppl. 1: 270–4PubMedGoogle Scholar
  204. 204.
    Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35Suppl. 1: 22–8PubMedGoogle Scholar
  205. 205.
    Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35Suppl. 1: 39–43PubMedGoogle Scholar
  206. 206.
    Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35Suppl. 1: 35–8PubMedGoogle Scholar
  207. 207.
    Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammo-pharmacology 1996; 4: 71–8Google Scholar
  208. 208.
    Distel M, Mueller C, Bluhmki E, et al. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35Suppl. 1: 68–77PubMedGoogle Scholar
  209. 209.
    Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996; 25Suppl. 102: 29–37Google Scholar
  210. 210.
    Benett A, Tavares IA. NSAIDs, COX-2 inhibitors, and the gut [letter]. Lancet 1995; 346: 1105Google Scholar
  211. 211.
    Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8PubMedGoogle Scholar
  212. 212.
    Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785–9PubMedGoogle Scholar
  213. 213.
    Kargman SL, O’Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556–9PubMedGoogle Scholar
  214. 214.
    Tsujii M, DuBois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501PubMedGoogle Scholar
  215. 215.
    Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–89PubMedGoogle Scholar
  216. 216.
    Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colocancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816–20PubMedGoogle Scholar
  217. 217.
    Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6PubMedGoogle Scholar
  218. 218.
    Thun MJ, Namboodiri MM, Call EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–7PubMedGoogle Scholar
  219. 219.
    Giovannuci E, Rimm EB, Stampfer MJ, et al. Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–6Google Scholar
  220. 220.
    Peleg II, Hilda T, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394–9PubMedGoogle Scholar
  221. 221.
    Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847–54PubMedGoogle Scholar
  222. 222.
    Shiff SJ, Koutsos MI, Qiao L, et al. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 22: 179–88Google Scholar
  223. 223.
    Pasricha PJ, Bedi A, O’Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994–8PubMedGoogle Scholar
  224. 224.
    Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995; 333: 656–8PubMedGoogle Scholar
  225. 225.
    Planas AM, Soriano MA, Rodriguez-Farre E, et al. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett 1995; 200: 187–90PubMedGoogle Scholar
  226. 226.
    Chen J, Marsh T, Zhang JS, et al. Expression of cyclooxygenase 2 in rat brain following kainate treatment. Neuroreport 1995; 6: 245–8PubMedGoogle Scholar
  227. 227.
    Adams J, Collaço-Moraes Y, De Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66: 6–13PubMedGoogle Scholar
  228. 228.
    Spence P, Franco R, Wood A, et al. Mechanisms of apoptosis as drug targets in the central nervous system. Expert Opin Ther Patents 1996; 6: 345–66Google Scholar
  229. 229.
    Tocco G, Freire-Moar J, Aisen PS, et al. Inflammation and alzheimer’s disease: the role of cyclooxygenase-2 (COX-2). In: William Harvey Research Conferences. New targets in inflammation: inhibitors of COX-2 or adhesion molecules [abstract P16]. New-Orleans, 1996; vol. 8: 37Google Scholar
  230. 230.
    Hampel H, Müller N. Inflammatory and immunological mechanisms in Alzheimer’s disease. Drug News Perspect 1995; 8: 599–608Google Scholar
  231. 231.
    Cochran FR, Vitek MR. Neuroinflammatory mechanisms in Alzheimer’s disease: new opportunities for drug discovery. Expert Opin Invest Drugs 1996; 5: 449–55Google Scholar
  232. 232.
    Fricker J. NSAIDs may reduce risk of Alzheimer’s disease [editorial]. Lancet 1996; 347: 958Google Scholar
  233. 233.
    Norris SH. Renal eicosanoids. Semin Nephrol 1990; 10: 64–88PubMedGoogle Scholar
  234. 234.
    Toto RD. The role of prostaglandins in NSAID induced renal dysfunction. J Rheumatol 1991; 18Suppl. 28: 22–5Google Scholar
  235. 235.
    Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 1993; 13: 7–16PubMedGoogle Scholar
  236. 236.
    Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in the renal cortex. Am J Physiol 1978; 235: F451–7PubMedGoogle Scholar
  237. 237.
    Rzymkiewicz D, Leingang K, Baird N, et al. Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1β. Am J Physiol 1994; 266: F39–45PubMedGoogle Scholar
  238. 238.
    Hughes AK, Padilla E, Kutchera WA, et al. Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells. Kidney Int 1995; 47: 53–61PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Jean-Yves Jouzeau
    • 1
  • Bernard Terlain
    • 1
  • Amr Abid
    • 1
  • Emmanuelle Nédélec
    • 1
  • Patrick Netter
    • 1
  1. 1.Faculté de MédecineLaboratoire de Pharmacologie et URA CNRS 1288Vandoeuvre lès NancyFrance

Personalised recommendations